Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
700 participants
Sep 25, 2018
OBSERVATIONAL
Conditions
Summary
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.
Eligibility
Inclusion Criteria2
- Patients treated with OAV-101 with a genetically confirmed diagnosis of SMA regardless of the date of diagnosis.
- Appropriate consent/assent has been obtained for participation in the registry
Exclusion Criteria2
- \- Currently enrolled in an interventional clinical trial involving an investigational medicinal product to treat SMA.
- Note: Patients who are participating in a Compassionate Use Program (CUP) for OAV-101 (Zolgensma) such as a Managed Access Program (MAP), an Expanded Access Program (EAP), Single Patient Investigational New Drug (IND) (SPI) or Named Patient Program (NPP) are eligible to enroll in the registry regardless of the date of a genetic or clinical diagnosis of SMA.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
Locations(99)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04174157